Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Zacks Research issued their Q1 2027 EPS estimates for shares of Arrowhead Pharmaceuticals in a research note issued on Wednesday, November 18th. Zacks Research analyst D. Bautz expects that the biotechnology company will earn ($1.39) per share for the quarter. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($5.07) per share. Zacks Research also issued estimates for Arrowhead Pharmaceuticals' Q2 2027 earnings at ($1.42) EPS, Q3 2027 earnings at ($1.32) EPS, Q4 2027 earnings at ($1.64) EPS and FY2029 earnings at ($2.02) EPS.
ARWR has been the topic of a number of other research reports. HC Wainwright restated a "buy" rating and issued a $120.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Thursday, October 15th. Piper Sandler reissued an "overweight" rating and issued a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research report on Thursday, July 23rd. Morgan Stanley boosted their target price on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an "overweight" rating in a research report on Thursday, July 23rd. Chardan Capital restated a "buy" rating and set a $115.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Thursday, October 15th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Arrowhead Pharmaceuticals in a report on Friday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $98.71.
Get Our Latest Report on ARWR
Arrowhead Pharmaceuticals Stock Performance
Shares of ARWR opened at $43.65 on Friday. The company has a market capitalization of $6.17 billion, a PE ratio of -8.54 and a beta of 1.34. The company has a debt-to-equity ratio of 16.61, a quick ratio of 4.11 and a current ratio of 4.14. The company's 50 day moving average price is $60.06 and its 200 day moving average price is $70.49. Arrowhead Pharmaceuticals has a 52 week low of $37.06 and a 52 week high of $95.49.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in Arrowhead Pharmaceuticals in the 2nd quarter valued at $1,208,838,000. Jupiter Topco LLC bought a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth about $99,623,000. Renaissance Technologies LLC bought a new position in shares of Arrowhead Pharmaceuticals during the 1st quarter worth about $64,988,000. Bank of New York Mellon Corp bought a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth about $70,061,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at about $50,990,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.
About Arrowhead Pharmaceuticals
(
Get Free Report)
Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company's research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.
While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.